Cancer megafunds with in silico and in vitro validation

Accelerating cancer drug discovery via financial engineering without financial crisis

Xianjin Yang, Edouard Debonneuil, Alex Zhavoronkov, Bhubaneswar Mishra

Research output: Contribution to journalArticle

Abstract

Advances in financial engineering are radically reshaping the biomedical marketplace. For instance, new methods of pooling diversified drug development programs by placing them in a special purpose vehicle (SPV) have been proposed to create a securitized cancer megafund allowing for debt and equity participation. In this study, we perform theoretical and numerical simulations that highlight the role of empirical validation of the projects comprising a cancer megafund. We quantify the degree to which the deliberately designed structure of derivatives and investments is key to its liquidity. Research megafunds with comprehensive in silico and laboratory validation protocols and ability to issue both debt, and equity as well as hybrid financial products may enable conservative investors including pension funds and sovereign government funds to profit from unique securitization opportunities. Thus, while hedging investor's longevity risk, such well-validated megafunds will contribute to health, well being and longevity of the global population.

Original languageEnglish (US)
Pages (from-to)57671-57678
Number of pages8
JournalOncotarget
Volume7
Issue number36
DOIs
StatePublished - 2016

Fingerprint

Financial Management
Drug Discovery
Computer Simulation
Pensions
Neoplasms
Health
Research
Pharmaceutical Preparations
Population
In Vitro Techniques

Keywords

  • Cancer megafund
  • In silico validation
  • Megafund
  • RBO
  • Research-backed obligation

ASJC Scopus subject areas

  • Oncology

Cite this

Cancer megafunds with in silico and in vitro validation : Accelerating cancer drug discovery via financial engineering without financial crisis. / Yang, Xianjin; Debonneuil, Edouard; Zhavoronkov, Alex; Mishra, Bhubaneswar.

In: Oncotarget, Vol. 7, No. 36, 2016, p. 57671-57678.

Research output: Contribution to journalArticle

@article{d9728e64b11842669536f58cf4f78d20,
title = "Cancer megafunds with in silico and in vitro validation: Accelerating cancer drug discovery via financial engineering without financial crisis",
abstract = "Advances in financial engineering are radically reshaping the biomedical marketplace. For instance, new methods of pooling diversified drug development programs by placing them in a special purpose vehicle (SPV) have been proposed to create a securitized cancer megafund allowing for debt and equity participation. In this study, we perform theoretical and numerical simulations that highlight the role of empirical validation of the projects comprising a cancer megafund. We quantify the degree to which the deliberately designed structure of derivatives and investments is key to its liquidity. Research megafunds with comprehensive in silico and laboratory validation protocols and ability to issue both debt, and equity as well as hybrid financial products may enable conservative investors including pension funds and sovereign government funds to profit from unique securitization opportunities. Thus, while hedging investor's longevity risk, such well-validated megafunds will contribute to health, well being and longevity of the global population.",
keywords = "Cancer megafund, In silico validation, Megafund, RBO, Research-backed obligation",
author = "Xianjin Yang and Edouard Debonneuil and Alex Zhavoronkov and Bhubaneswar Mishra",
year = "2016",
doi = "10.18632/oncotarget.9808",
language = "English (US)",
volume = "7",
pages = "57671--57678",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "36",

}

TY - JOUR

T1 - Cancer megafunds with in silico and in vitro validation

T2 - Accelerating cancer drug discovery via financial engineering without financial crisis

AU - Yang, Xianjin

AU - Debonneuil, Edouard

AU - Zhavoronkov, Alex

AU - Mishra, Bhubaneswar

PY - 2016

Y1 - 2016

N2 - Advances in financial engineering are radically reshaping the biomedical marketplace. For instance, new methods of pooling diversified drug development programs by placing them in a special purpose vehicle (SPV) have been proposed to create a securitized cancer megafund allowing for debt and equity participation. In this study, we perform theoretical and numerical simulations that highlight the role of empirical validation of the projects comprising a cancer megafund. We quantify the degree to which the deliberately designed structure of derivatives and investments is key to its liquidity. Research megafunds with comprehensive in silico and laboratory validation protocols and ability to issue both debt, and equity as well as hybrid financial products may enable conservative investors including pension funds and sovereign government funds to profit from unique securitization opportunities. Thus, while hedging investor's longevity risk, such well-validated megafunds will contribute to health, well being and longevity of the global population.

AB - Advances in financial engineering are radically reshaping the biomedical marketplace. For instance, new methods of pooling diversified drug development programs by placing them in a special purpose vehicle (SPV) have been proposed to create a securitized cancer megafund allowing for debt and equity participation. In this study, we perform theoretical and numerical simulations that highlight the role of empirical validation of the projects comprising a cancer megafund. We quantify the degree to which the deliberately designed structure of derivatives and investments is key to its liquidity. Research megafunds with comprehensive in silico and laboratory validation protocols and ability to issue both debt, and equity as well as hybrid financial products may enable conservative investors including pension funds and sovereign government funds to profit from unique securitization opportunities. Thus, while hedging investor's longevity risk, such well-validated megafunds will contribute to health, well being and longevity of the global population.

KW - Cancer megafund

KW - In silico validation

KW - Megafund

KW - RBO

KW - Research-backed obligation

UR - http://www.scopus.com/inward/record.url?scp=84988354717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988354717&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9808

DO - 10.18632/oncotarget.9808

M3 - Article

VL - 7

SP - 57671

EP - 57678

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 36

ER -